Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial

Roffe, C.; Warusevitane, A.; Smith, C.; Dixit, A.; Sprigg, N.; Ogollah, R.; Sim, J.; Jowett, S.; Helliwell, B.; Phillips, N.; Mhlanga, I.; Havard, D.; Kurlak, L.; Skinner, C.; Palmer, J.; Thomson, M.; Latulipe, C.; Haywood, L.; Woodhouse, L.; Bath, P.

Abstract

The research study is designed to assess a treatment which might prevent pneumonia and improve survival in patients that have had a stroke.
Pneumonia is a major cause of death after stroke and delays recovery in survivors. The most important cause of pneumonia in stroke patients is inhalation of regurgitated or vomited stomach content. A small study has shown metoclopramide, a drug which prevents vomiting and regurgitation could reduce pneumonia after stroke. The purpose of this study is to confirm this and to test whether this treatment can reduce pneumonia, improve neurological outcome and survival after stroke. The trial will also assess whether the treatment is cost-effective.
Participants will be assigned at random to the trial treatment (metoclopramide) or control (dummy treatment). The trial treatment will be given for three times a day via a feeding tube or intravenously for 14 days. Data on participants will be collected for the first 14 days and at 6 months post -stroke.

Citation

Roffe, C., Warusevitane, A., Smith, C., Dixit, A., Sprigg, N., Ogollah, R., …Bath, P. (2023, October). Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial. Poster presented at 15th World Stroke Congress, Toronto, Canada

• Presentation Conference Type: Poster
• Conference Name: 15th World Stroke Congress
• Conference Location: Toronto, Canada
• Start Date: Oct 10, 2023
• End Date: Oct 12, 2023
• Deposit Date: Apr 15, 2024
• Publisher URL: https://journals.sagepub.com/doi/full/10.1177/17474930231192010